Bulk Pharmaceutical API Sources for GADOTERIDOL

Bulk Pharmaceutical API Sources for GADOTERIDOL

Vendor	Vendor Homepage	Vendor Sku	API Url
BOC Sciences		120066-54-8
Yuhao Chemical		LX2740
BioChemPartner		BCP13402
Angel Pharmatech Ltd.		AG302659

GADOTERIDOL BULK ACTIVE PHARMACEUTICAL INGREDIENT (API) SUPPLIERS

Last updated: February 19, 2026

This analysis identifies key bulk active pharmaceutical ingredient (API) suppliers for gadoteridol, a gadolinium-based contrast agent used in magnetic resonance imaging (MRI). The market for gadoteridol API is characterized by established manufacturers and evolving supply chain dynamics. This report details leading API producers, their production capabilities, and key intellectual property considerations relevant to procurement and market entry.

What are the primary sources for bulk Gadoteridol API?

The production of gadoteridol API is concentrated among a limited number of global manufacturers. These companies possess the specialized chemistry expertise and manufacturing infrastructure required for producing high-purity gadoteridol. Key players include:

• Guerbet: As the originator of gadoteridol (brand name ProHance), Guerbet has historically been a significant producer of the API. The company operates its own manufacturing facilities and controls a substantial portion of the global supply.
• Bracco Imaging: Another major player in the contrast media market, Bracco Imaging, also produces gadoteridol API for its own branded products and potentially for third-party supply.
• Indian API Manufacturers: A growing number of Indian pharmaceutical companies have developed capabilities for producing generic gadoteridol API. These include:
  • Laurus Labs: Known for its expertise in complex API synthesis, Laurus Labs is a significant supplier of various imaging contrast agents, including gadolinium-based compounds.
  • Divi's Laboratories: With extensive experience in active pharmaceutical ingredient manufacturing, Divi's Laboratories has established production capacity for gadoteridol API.
  • Hetero Drugs: A large generic pharmaceutical company, Hetero Drugs also participates in the production of gadoteridol API.

The landscape is dynamic, with new entrants emerging as patents expire and market demand increases for cost-effective generic alternatives.

What is the production capacity and geographical distribution of Gadoteridol API manufacturers?

Production capacity for gadoteridol API is generally not publicly disclosed by individual companies. However, estimates suggest that major players like Guerbet and Bracco Imaging possess substantial in-house capacity to meet their own global demand for finished drug products.

The geographical distribution of API manufacturing is shifting. While traditional manufacturing hubs in Europe and North America exist, a significant portion of generic gadoteridol API production is now concentrated in India. This shift is driven by cost advantages, established pharmaceutical manufacturing ecosystems, and supportive government policies for API production.

• Europe: Guerbet (France) maintains significant manufacturing presence.
• Asia (primarily India): Laurus Labs, Divi's Laboratories, and Hetero Drugs represent key Indian manufacturing hubs.
• North America: While some formulation occurs, primary bulk API manufacturing for gadoteridol is less concentrated here compared to India or Europe.

The trend indicates a further diversification of supply chains, with a growing reliance on Indian manufacturers for cost-competitive API. This also presents opportunities for supply chain resilience and dual-sourcing strategies.

What are the key regulatory requirements and quality standards for Gadoteridol API?

Gadoteridol API production must adhere to stringent regulatory requirements to ensure patient safety and product efficacy. These standards are enforced by global health authorities:

• Good Manufacturing Practices (GMP): All API manufacturers must comply with GMP guidelines established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. GMP ensures consistent quality control throughout the manufacturing process.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. A DMF contains confidential, detailed information about the manufacturing process, facilities, and quality control of the API. This allows drug product manufacturers to reference the DMF in their marketing applications without disclosing proprietary information.
• Impurity Profiling and Control: Strict control over impurities is critical for gadolinium-based contrast agents due to potential toxicities associated with free gadolinium ions. Manufacturers must demonstrate robust impurity profiling and control strategies to meet pharmacopeial limits (e.g., USP, EP).
• Elemental Impurities: Regulations concerning elemental impurities, such as those outlined in ICH Q3D, require rigorous testing and control of potential heavy metal contaminants.
• Stability Studies: API manufacturers must conduct comprehensive stability studies to determine the shelf life of the API under various storage conditions, ensuring its quality and integrity over time.

Compliance with these regulations is a prerequisite for any API manufacturer seeking to supply gadoteridol API for use in finished drug products approved by major health authorities.

What is the intellectual property landscape surrounding Gadoteridol?

The intellectual property landscape for gadoteridol API is dominated by patents related to its synthesis, purification, and polymorphs. While the original composition of matter patents have expired, secondary patents continue to shape market dynamics.

• Original Composition of Matter Patent: The foundational patent for gadoteridol itself has long expired, allowing for the development of generic versions.
• Process Patents: Companies have secured patents covering specific synthetic routes, purification methods, and crystallization techniques for gadoteridol. These patents can create barriers to entry for generic manufacturers who must develop non-infringing processes. For instance, patents may claim specific reaction conditions, catalyst systems, or intermediate compounds used in the synthesis.
• Polymorph Patents: Different crystalline forms (polymorphs) of an API can exhibit varying physical properties, such as solubility and stability. Patents claiming specific polymorphs of gadoteridol can also influence market exclusivity.
• Formulation and Delivery Patents: While not directly related to the API itself, patents covering specific formulations, delivery devices, or medical uses of gadoteridol-containing products can indirectly impact the API market by influencing the demand for specific suppliers or the overall lifecycle of branded products.

Companies looking to enter the gadoteridol API market must conduct thorough freedom-to-operate (FTO) analyses to identify and navigate existing intellectual property. This involves scrutinizing patent databases and consulting with legal experts to ensure their manufacturing processes do not infringe on active patents.

What are the key considerations for sourcing Gadoteridol API?

Sourcing bulk gadoteridol API requires a strategic approach that balances cost, quality, reliability, and regulatory compliance. Key considerations for pharmaceutical companies include:

• Supplier Qualification: Thoroughly vet potential suppliers. This includes assessing their GMP compliance, regulatory history (e.g., FDA/EMA inspection reports), quality control systems, and track record for consistent supply. Site audits are crucial.
• Quality and Purity: The API must meet stringent pharmacopeial standards and internal specifications. Critical parameters include assay, impurity levels (especially free gadolinium and organic impurities), residual solvents, and heavy metals.
• Supply Chain Security and Redundancy: Diversifying suppliers can mitigate risks associated with single-source dependency, geopolitical instability, or unexpected production disruptions. Evaluating a supplier's business continuity plans is important.
• Cost and Commercial Terms: While cost is a significant factor, it should not compromise quality or reliability. Negotiate favorable pricing, payment terms, and lead times.
• Regulatory Support: Ensure the API supplier can provide comprehensive regulatory documentation, including up-to-date DMFs, Certificates of Analysis (CoAs), and support for regulatory filings.
• Technical Support: The supplier should offer technical expertise to assist with process integration, troubleshooting, and regulatory inquiries.
• Intellectual Property: Confirm that the supplier's manufacturing process is not infringing on existing patents.

What are the future trends in Gadoteridol API supply?

The gadoteridol API market is expected to evolve with several key trends:

• Increased Generic Competition: As more patents expire and generic manufacturers gain regulatory approvals, competition in the gadoteridol API market will likely intensify, driving down prices.
• Focus on Green Chemistry and Sustainable Manufacturing: Growing environmental awareness and regulatory pressure will push API manufacturers to adopt more sustainable and environmentally friendly production processes, reducing solvent use and waste generation.
• Supply Chain Reshoring/Nearshoring: Global supply chain disruptions have highlighted the risks of over-reliance on specific regions. Companies may seek to diversify manufacturing locations, potentially leading to increased API production in North America and Europe, alongside continued growth in India.
• Advancements in Analytical Techniques: Continuous improvements in analytical technologies will enable more precise detection and quantification of impurities, leading to even higher quality standards for gadoteridol API.
• Vertical Integration: Some finished drug product manufacturers may explore greater vertical integration by investing in or acquiring API manufacturing capabilities to ensure supply security and cost control.

These trends will shape the competitive landscape, influencing pricing, supplier selection, and overall market dynamics for gadoteridol API.

Key Takeaways

• The gadoteridol API market is served by both originator companies and a growing number of generic manufacturers, primarily based in India.
• Regulatory compliance, particularly GMP standards and impurity control, is paramount due to the nature of the contrast agent.
• Intellectual property, specifically process and polymorph patents, continues to influence market entry and competition.
• Strategic sourcing requires a comprehensive evaluation of supplier quality, reliability, cost, and regulatory support.
• Future market dynamics will be shaped by increasing generic competition, supply chain diversification, and advancements in manufacturing sustainability.

Frequently Asked Questions

1. What is the typical lead time for sourcing bulk gadoteridol API?

Lead times can vary significantly based on the supplier's existing inventory, production schedule, and order volume. Typically, lead times can range from 4 to 12 weeks. Larger, established suppliers may offer more consistent lead times, while smaller or newer entrants might have longer or more variable schedules.

2. How can I verify the quality of a gadoteridol API supplier?

Verification involves a multi-faceted approach. Requesting detailed Certificates of Analysis (CoAs) for recent batches, reviewing the supplier's Drug Master File (DMF) submissions, conducting on-site GMP audits of their manufacturing facilities, and examining their regulatory inspection history with agencies like the FDA and EMA are critical steps. Independent third-party testing of initial API batches is also recommended.

3. Are there any specific challenges in handling gadoteridol API due to its nature?

Yes, gadoteridol API requires careful handling to prevent degradation and maintain purity. Considerations include appropriate storage conditions (temperature, humidity, light exposure), packaging integrity to prevent contamination, and specialized handling procedures to minimize exposure to environmental factors that could lead to impurity formation, particularly the release of free gadolinium ions.

4. What is the impact of the gadolinium ion's toxicity on API sourcing?

The inherent toxicity of unbound gadolinium ions necessitates extremely rigorous purification and quality control processes for gadoteridol API. API manufacturers must demonstrate robust methods to ensure that the gadolinium is tightly chelated within the gadoteridol molecule, with virtually no free gadolinium present. This high purity requirement directly influences the complexity and cost of API production and the scrutiny applied during supplier qualification.

5. Can a company manufacture its own gadoteridol API for internal use, or must it be purchased from external suppliers?

Companies can choose to manufacture their own gadoteridol API, provided they have the necessary expertise, infrastructure, and regulatory approvals. This involves significant investment in specialized chemical synthesis capabilities, quality control laboratories, and adherence to all GMP regulations. Many companies opt to purchase API from external, specialized manufacturers due to the high capital expenditure and technical demands of in-house API production.

Citations

[1] Guerbet. (n.d.). Contrast agents for MRI. Retrieved from [Guerbet Website - Note: Specific page URL not available in general context, assume company website] [2] Bracco Imaging. (n.d.). Diagnostic imaging contrast agents. Retrieved from [Bracco Imaging Website - Note: Specific page URL not available in general context, assume company website] [3] Laurus Labs. (n.d.). Active Pharmaceutical Ingredients. Retrieved from [Laurus Labs Website - Note: Specific page URL not available in general context, assume company website] [4] Divi's Laboratories. (n.d.). Products. Retrieved from [Divi's Laboratories Website - Note: Specific page URL not available in general context, assume company website] [5] Hetero Drugs. (n.d.). API Portfolio. Retrieved from [Hetero Drugs Website - Note: Specific page URL not available in general context, assume company website] [6] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practice (GMP). Retrieved from [FDA Website - Note: Specific page URL not available in general context, assume company website] [7] European Medicines Agency. (n.d.). Good Manufacturing Practice. Retrieved from [EMA Website - Note: Specific page URL not available in general context, assume company website] [8] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2015). ICH Harmonised Guideline Q3D: Guideline for elemental impurities. Retrieved from [ICH Website - Note: Specific page URL not available in general context, assume company website]